In today’s episode, we welcome Clarke Futch, Chairman and CEO of HealthCare Royalty Partners, or HCRx, with a thirty year track record in biopharma investing.
The treatment drug to address insatiable hunger in people with Prader-Willi syndrome was greenlit this year. Discover five therapies in line for approval.
We were on the ground in Barcelona speaking to biotech companies, university technology transfer offices, and top pharma firms about their experience at BIOSPAIN and their progress towards securing partnerships.
Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells. This enables in vivo or ex vivo delivery via a single viral vector. Epic’s lead program, EPI-321, is in IND-enabling studies […]